Veterinary Orthobiologics Market Size, Share & Trends Analysis Report By Mode of Delivery (Intra-muscular/Intra-lesional, Intra-articular), By Product, By Animal, By Application, By End Use, By Region, And Segment Forecasts, 2024 - 2030

Veterinary Orthobiologics Market Size, Share & Trends Analysis Report By Mode of Delivery (Intra-muscular/Intra-lesional, Intra-articular), By Product, By Animal, By Application, By End Use, By Region, And Segment Forecasts, 2024 - 2030

Veterinary Orthobiologics Market Growth & Trends

The global veterinary orthobiologics market size is expected to reach USD 1.24 billion by 2030, registering a CAGR of 8.82% from 2024 to 2030, according to a new report by Grand View Research, Inc. Two crucial factors driving the market growth are the increasing number of clinical trials in orthobiologics and the rising prevalence of orthopedic complications in animals. The industry has experienced a steady rise in clinical trials for novel orthobiologics in treating veterinary orthopedic complications in recent years. For instance, in June 2024, the U.S. FDA approved initiating stem cell clinical trials for dogs & horses. This trial will be conducted by Cornell University Hospital for Animals (CUHA). It will explore the effectiveness of stem cells in treating neurological and musculoskeletal complications in canine & equine species. The study will extract the participants' allogenic adipose or bone marrow-derived mesenchymal stem cells and use them to treat nerve, muscle, and other conditions.

The data gathered from this study will help develop clinical evidence-based products in veterinary regenerative medicine. Furthermore, Cell Therapy Tools initiated another clinical trial in June 2024. In the pre-clinical studies, the company's product, Chrondroshield, the participants' dogs responded well to the therapy, showing improvements in OA without side effects. This latest clinical trial phase aims to recruit more canine participants for further testing. This product uses cytokine and growth factors inside the dog's platelets to trigger a healing response in the affected area and assist in cartilage repair. These ongoing advancements showcase the market’s ever-evolving nature, with many growth opportunities. Studies like these help create novel products for treating orthopedic conditions with a thoroughly scrutinized base of evidence, providing the market with substantial growth prospects.

In addition, throughout the globe, orthopedic conditions are becoming increasingly common in animals. For instance, according to a 2024 Plos One published study, multiple researchers collaborated to initiate a “Dog Aging Project” to map out and understand disease patterns in dogs throughout their lives. The project determined that the prevalence of orthopedic conditions, if left untreated, increases as the age of the dogs progresses, i.e., prevalence at age 1 - 1% and prevalence at age 11 & above - 39%. The dogs with higher weight, i.e., more than 30 kgs, were determined to have a higher prevalence of orthopedic conditions (23%), thus establishing a correlation between obesity and orthopedic diseases. Furthermore, according to a 2023 publication in NCBI, the prevalence of Osteoarthritis (OA) in cats was estimated at around 60%. Those diagnosed with OA were reported to be suffering from associated conditions, such as joint pain, joint deformity, lameness, etc. These symptoms were determined to be on the higher side in overweight cats. All these factors collectively point toward the need for appropriate orthobiologics like stem cells, platelet-rich plasma (PRP), and monoclonal antibody (mAb) to treat this rise in orthopedic complications in animals.

Veterinary Orthobiologics Market Report Highlights

• The PRP product segment accounted for the largest revenue share of 39.2% in 2023. In animals, platelets are vital in multiple processes, such as immune response, angiogenesis, and tissue repair. PRP is employed to promote the healing process in blood clotting as it contains proteins & growth factors that speed up the healing of the tendons & ligaments by speeding up the growth of new tissues
• The canine animal segment dominated the market with a share of 46.1% in 2023 due to the high adoption rate, rising cases of sports-related injuries in dogs, and high prevalence of OA in dogs (40%) and lameness in 1 in 5 dogs (Zoetis, 2024 data)
• The OA application segment dominated the market with a share of over 60% in 2023 because of the high prevalence of OA and rise in contributing factors to OA in dogs, cats, and horses. OA is becoming one of the most prevalent conditions in animals. The main causative factors for OA can be obesity, breed, lack of exercise & proper diet, and genetic predisposition
• The intra-articular delivery mode segment dominated the market in 2023. This dominance can be attributed to its demand as it can be directly delivered into the joint to ensure faster action and increase drug bioavailability. In veterinary medicine, intra-articular administration of orthobiologics is an established process for managing joint pain and lameness
• Based on the end use, the veterinary hospitals segment dominated the market in terms of share in 2023 due to the increased number of patients receiving treatment for orthopedic medical conditions in animals at these hospitals. To administer orthobiologics at the necessary location, specific equipment and skilled staff are essential. Overall, the availability of therapies, skilled personnel, and specialized equipment at the hospital pharmacy in a single location is advantageous to animal owners
• North America accounted for the largest share of 43.23% in 2023. This dominance can be attributed to the high pet adoption rate, higher animal health awareness among owners, rising spending on animal health, and the presence of major companies, such as Zoetis, VetStem Inc., Enso Discoveries, and Ardent Animal Health
• The Asia Pacific APAC regional market is expected to grow at the highest CAGR of over 10.09% from 2024 to 2030 due to increasing ingenuity in R&D activities in major countries like Japan, China, and India

Please note The report will be delivered in 2-3 business days upon order notification.